What’s the current market cap for MBX Biosciences, Inc. stock?

MBX Biosciences, Inc. (MBX) has a market cap of $1.9bn as of June 17, 2026.

What is the P/E ratio for MBX Biosciences, Inc. stock?

The price to earnings (P/E) ratio for MBX Biosciences, Inc. (MBX) stock is 0 as of June 17, 2026.

Does MBX Biosciences, Inc. stock pay dividends?

No, MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next MBX Biosciences, Inc. dividend payment date?

MBX Biosciences, Inc. (MBX) stock does not pay dividends to its shareholders.

What is the beta indicator for MBX Biosciences, Inc.?

MBX Biosciences, Inc. (MBX) does not currently have a Beta indicator.

Buy MBX Biosciences, Inc. stock | $MBX Share Price

13:30

15:10

16:45

18:25

20:00

About MBX Biosciences, Inc.

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.

Ticker

$MBX

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

Carmel, United States

Website

mbxbio.com

MBX Metrics

BasicAdvanced

$1.9bn

-$2.18

Bulls say / Bears say

One-year open-label extension data for once-weekly canvuparatide demonstrated maintained serum calcium normalization, renal function improvement, and a 90% retention rate, de-risking the Phase 3 initiation slated for Q3 2026 (Reuters)

MBX expects its cash, cash equivalents, and marketable securities balance of approximately $374 million at end-2025 to fund operations into 2029, minimizing near-term dilution risk and supporting late-stage development (Reuters)

Preliminary Phase 1 data for obesity candidate MBX 4291 showed mean weight loss of 7% at eight weeks and a 26-day half-life supporting potential once-monthly dosing, diversifying MBX’s pipeline beyond hypoparathyroidism (Reuters)

Responder rate for canvuparatide fell from 63% at 12 weeks to 57% at one year in the open-label extension, raising concerns about waning efficacy over prolonged treatment (Reuters)

Shares plunged 19.6% in premarket trading upon release of the one-year extension data, reflecting investor disappointment and market skepticism over the trial outcomes (Reuters)

MBX was expected to post an EPS loss of $0.58 for Q1 2026, underscoring continued unprofitability and high cash burn in advance of any product revenue (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 15 Jun 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MBX

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

Responder rate for canvuparatide fell from 63% at 12 weeks to 57% at one year in the open-label extension, raising concerns about waning efficacy over prolonged treatment (Reuters)

Shares plunged 19.6% in premarket trading upon release of the one-year extension data, reflecting investor disappointment and market skepticism over the trial outcomes (Reuters)

MBX was expected to post an EPS loss of $0.58 for Q1 2026, underscoring continued unprofitability and high cash burn in advance of any product revenue (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 15 Jun 2026.